Katie Insogna > DLA Piper LLP (US) > Boston, United States > Lawyer Profile
DLA Piper LLP (US) Offices
33 ARCH STREET
26TH FLOOR
BOSTON MA 02110-1447
MASSACHUSETTS
United States
- Firm Profile
- Go to...
Katie Insogna
Work Department
Litigation, Arbitration and Investigations; Healthcare; Life Sciences; Life Science Litigation
Position
Partner; Co-Chair, Pharmaceutical and Medical Device Product Liability Sub-practice Group
Career
Katie Insogna serves as Co-Chair of the Pharmaceutical and Medical Device Product Liability Sub-Practice Group. Katie’s practice focuses on litigation, regulatory, and enforcement challenges facing pharmaceutical, medical device, and life science companies. Her litigation practice primarily involves representing clients in complex, multi-jurisdictional product liability litigation and complex commercial litigation, for which DLA Piper’s Product Liability and Mass Tort practice group has been recognized as a leader for years.
Katie has extensive expertise with fact and expert witness development, discovery and dispositive motion practice, and trial preparation. Katie has taken and defended numerous party and third-party witness depositions in product liability and commercial litigation cases. She also has argued motions in state and federal courts.
In addition to her litigation practice, Katie counsels clients on research and development, risk management, and other compliance issues.
Education
J.D., University of Southern California Gould School of Law; B.A., Georgetown University
Lawyer Rankings
United States > Healthcare > Life sciences
(Next Generation Partners)DLA Piper LLP (US) handles a range of high value disputes in the sector, helping clients defend their patents in cross-border litigation and also providing support in product liability and personal injury MDLs arising out of allegations of faulty products or drugs. Licensing and supply agreements also fall within the group’s purview, where the group acts for both suppliers and buyers of critical medical ingredients. Heading the team are Matthew Holian, a Boston-based litigator whose practice encompasses multi-jurisdictional product liability disputes, and New York’s Andrew Gilbert, who advises both public and private life sciences companies on M&As and securities law; February 2024 saw the arrival of FDA regulatory specialists Vernessa Pollard and Anisa Mohanty from McDermott Will & Emery LLP‘s Washington office, advising on pre-market strategy and post-market compliance. Loren Brown represents clients across the spectrum of litigation pertinent to life sciences clients, including patent and trade secret infringement claims, and securities class actions, and Lucas Przymusinski focusing on product liability suits tied to drugs and medical devices; both are located in New York. Boston’s Katie Insogna is recommended for her ability to handle both regulatory issues and litigation, including MDLs tied to product liability, and broader commercial litigation.
United States > Dispute resolution > Product liability, mass tort and class action - defense: pharmaceuticals and medical devices
(Next Generation Partners)Drawing upon lawyers with ‘first-hand medical practice experience and highly technical expertise’, DLA Piper LLP (US) combines strong procedural nous with deep subject matter knowledge, in turn being well positioned to represent life sciences clients on work throughout the litigation life cycle. As well as regularly acting as national co-ordinating counsel on large-scale domestic MDLs, the team regularly works alongside practitioners throughout its global network of offices on cross-border work, and is recognized for its ‘excellent‘ work in co-ordinating multinational law suits. In this context, ‘outstanding’ Atlanta-based Christopher Campbell continues to take the lead for Bayer on global mass tort litigation involving Essure, leveraging the knowledge and skills gleaned from the firm’s success in the initial US action to good effect on the ensuing international cases. Praised for her ‘ability to see the big picture’, as well as her ‘highly impressive knowledge of the medical facts’, Mary Gately in Washington DC has also been key to the firm’s success for Bayer. New York-based Loren Brown is well-versed in handling large-scale aggregated litigation, including his ongoing work as co-national counsel for Sanofi in the Zantac MDL; where he has gained an excellent reputation for securing the early dismissal of matters through often innovative strategies. From Boston, Matthew Holian is also very effective at representing pharmaceutical companies engaged in MDLs, being as comfortable handling discovery issues, as he is cross-examining expert witnesses in Daubert hearings and in bellwether trials. Other key individuals include Dallas-based trial lawyer Lyn Pruitt; Boston-based Katie Insogna, who excels at developing expert witnesses and on discovery matters; and New York based Lucas Przymusinski , who ‘has an incredibly scientific mind in addition to legal expertise’.
Lawyer Rankings
- Next Generation Partners United States > Dispute resolution > Product liability, mass tort and class action - defense: pharmaceuticals and medical devices
- Next Generation Partners United States > Healthcare > Life sciences
- Product liability, mass tort and class action - defense: pharmaceuticals and medical devices United States > Dispute resolution
- Life sciences United States > Healthcare
Top Tier Firm Rankings
- Media, technology and telecoms > Cyber law (including data privacy and data protection)
- Tax > International tax
- Real estate > Land use/zoning
- Investment fund formation and management > Alternative/hedge funds
- Media, technology and telecoms > Outsourcing
- Intellectual property > Patents: licensing
- Intellectual property > Patents: litigation (International Trade Commission)
- M&A/corporate and commercial > Private equity buyouts: middle-market (Up to $500m)
- Dispute resolution > Product liability, mass tort and class action - defense: pharmaceuticals and medical devices
- Real estate > Real estate
- International trade > CFIUS
- Government > State attorneys general
- Media, technology and telecoms > Telecoms and broadcast: regulatory
- Media, technology and telecoms > Telecoms and broadcast: transactions
Firm Rankings
- Media, technology and telecoms > Advertising and marketing: transactional and regulatory
- Insurance > Advice to insurers
- Industry focus > Cannabis
- Dispute resolution > E-discovery
- Tax > Financial products
- Finance > Fintech
- Intellectual property > Patents: litigation (full coverage)
- Dispute resolution > Product liability, mass tort and class action - defense: consumer products (including tobacco)
- Dispute resolution > Product liability, mass tort and class action - defense: toxic tort
- Real estate > Real estate investment trusts (REITs)
- Energy > Renewable/alternative power
- Finance > Structured finance: securitization
- Media, technology and telecoms > Technology transactions
- Intellectual property > Trademarks: non-contentious (including prosecution, portfolio management and licensing)
- Tax > US taxes: contentious
- M&A/corporate and commercial > Venture capital and emerging companies
- Labor and employment > Workplace and employment counseling
- Antitrust > Cartel
- Intellectual property > Copyright
- M&A/corporate and commercial > Corporate governance
- Labor and employment > Employee benefits, executive compensation and retirement plans: design
- Environment > Environment: regulatory
- Environment > Environment: transactional
- Insurance > Insurance: non-contentious
- Labor and employment > Labor and employment disputes (including collective actions)
- Labor and employment > Labor-management relations
- Healthcare > Life sciences
- Dispute resolution > M&A litigation: defense
- M&A/corporate and commercial > M&A: middle-market ($500m-999m)
- Media, technology and telecoms > Media and entertainment: transactional
- Intellectual property > Patents: prosecution (including re-examination and post-grant proceedings)
- Dispute resolution > Product liability, mass tort and class action - defense: automotive/transport
- Dispute resolution > Securities litigation: defense
- Intellectual property > Trademarks: litigation
- Tax > US taxes: non-contentious
- Finance > Capital markets: equity offerings
- Antitrust > Civil litigation/class actions: defense
- Real estate > Construction (including construction litigation)
- Labor and employment > Employee benefits, executive compensation and retirement plans: transactional
- Environment > Environment: litigation
- Dispute resolution > General commercial disputes
- Government > Government contracts
- Dispute resolution > International arbitration
- Investment fund formation and management > Private equity funds (including venture capital)
- Healthcare > Service providers
- Intellectual property > Trade secrets (litigation and non-contentious matters)
- Finance > Project finance
- M&A/corporate and commercial > M&A: large deals ($1bn+)
- Finance > Restructuring (including bankruptcy): corporate
- Dispute resolution > Corporate investigations and white-collar criminal defense
- International trade > CFIUS
- Transport > Rail and road: litigation and regulation